Phase 2 data show treatment efficacy in 'difficult-to-cure' hepatitis C patients

A hepatitis C (HCV) drug currently under investigation, ABT-493 and ABT-530, which is an all-oral once-daily antiviral treatment, helped HCV genotype 3 patients with heavily scarred livers and no previous treatment history to achieve a 100 percent sustained virologic response after receiving the treatment for 12 weeks (SVR12).